LDLR Antibody (F-7): sc-373830
- LDLR Antibody (F-7) is a mouse monoclonal IgG2a κ, cited in 6 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 13-47 near the N-terminus of LDLR of human origin
- recommended for detection of LDLR of human origin by WB, IP, IF and ELISA
- See LDLR (C7): sc-18823 for LDLR antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG2a BP-HRP are the preferred secondary detection reagents for LDLR Antibody (F-7) for WB applications. These reagents are now offered in bundles with LDLR Antibody (F-7) (see ordering information below).
QUICK LINKS
SEE ALSO...
LDLR Antibody (F-7) is a mouse monoclonal IgG2a antibody that detects low density lipoprotein receptor (LDLR) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-LDLR antibody (F-7) plays a crucial role in understanding LDLR function, which is essential for mediating low density lipoprotein (LDL) uptake and subsequent degradation in lysosomes, thereby providing necessary cholesterol to cells. LDLR (F-7) monoclonal antibody supports research into proper LDLR functioning, which is vital for maintaining cholesterol homeostasis, as dysfunction can lead to serious health issues, such as familial hypercholesterolemia (FH), a genetic disorder characterized by high cholesterol levels and increased risk of coronary atherosclerosis. LDLR protein is located on the cell surface as a transmembrane protein, where clustering in coated pits facilitates rapid endocytosis of bound LDL. This mechanism underscores LDLR importance in lipid metabolism and cardiovascular health, making LDLR (F-7) antibody an invaluable tool for researchers studying cholesterol regulation and related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LDLR Antibody (F-7) References:
- Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. | Do, R., et al. 2015. Nature. 518: 102-6. PMID: 25487149
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | Rakipovski, G., et al. 2018. JACC Basic Transl Sci. 3: 844-857. PMID: 30623143
- LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis. | Shi, X., et al. 2022. Clin Transl Med. 12: e711. PMID: 35083881
- RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels. | Clifford, BL., et al. 2023. Circ Res. 132: 849-863. PMID: 36876496
- Tanshinone IIA alleviates atherosclerosis in LDLR-/- mice by regulating efferocytosis of macrophages. | Wang, J., et al. 2023. Front Pharmacol. 14: 1233709. PMID: 37886125
- Cholesterol homeostasis confers glioma malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR. | Zhang, J., et al. 2024. Neuro Oncol. 26: 684-700. PMID: 38070488
- Sexual dimorphism in atherosclerotic plaques of aged Ldlr-/- mice. | Smit, V., et al. 2024. Immun Ageing. 21: 27. PMID: 38698438
- IL-1β Induces LDL Transcytosis by a Novel Pathway Involving LDLR and Rab27a. | Jang, E., et al. 2024. Arterioscler Thromb Vasc Biol. 44: 2053-2068. PMID: 38989581
- LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia. | Ibrahim, S., et al. 2024. Atherosclerosis. 397: 117610. PMID: 39085000
- Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis. | Rämö, JT., et al. 2024. Circulation. 150: 1767-1780. PMID: 39222019
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LDLR Antibody (F-7) | sc-373830 | 200 µg/ml | $322.00 | |||
LDLR Antibody (F-7): m-IgG Fc BP-HRP Bundle | sc-540403 | 200 µg Ab; 10 µg BP | $361.00 | |||
LDLR Antibody (F-7): m-IgG2a BP-HRP Bundle | sc-546903 | 200 µg Ab; 10 µg BP | $361.00 |